Leukemia, Chronic Myeloid
12
0
0
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
71.4%
-15.1% vs benchmark
33%
4 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
A Study on the Tolerability, Safety and Effectiveness of Asciminib in Patients With Philadelphia Chromosome-positive Chronic Myeloid Leukemia in the Chronic Phase in Germany
Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia (CML) in All Lines of Treatment
A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients
Study of Imatinib Discontinuation in Chronic Myeloid Leukemia With Deep Molecular Response
Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response
The EMPATHY Pilot Study
A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
Malaysia Stop Tyrosine Kinase Inhibitor Trial
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Chronic Myelod Leukemia Registry at Asan Medical Center
Evaluation of the Therapeutic Effect of HU Pulse Therapy for CML Patients
Multicenter, PhaseⅣ, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib